Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SYMPATICO
- Sponsors Pharmacyclics
- 26 Nov 2019 Planned number of patients changed from 287 to 362.
- 12 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated